Medicines and Healthcare products Regulatory Agency

What Medicines and Healthcare products Regulatory Agency does

Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the UK Department of Health and Social Care that serves as the statutory regulator for medicines, medical devices, and blood components for transfusion across the United Kingdom. Founded in 2003 and headquartered in London with 1,001–5,000 employees, MHRA's core functions include marketing authorisation for medicines and biologics, medical device market access, and post-market surveillance. Its portfolio of programmes includes the AI Airlock regulatory sandbox for AI-as-a-Medical-Device (launched 2024, Phase 2 cohort October 2025), the MHRA–NICE aligned pathway for streamlined medicine approval (March 2026), a consultation on long-term CE-marked medical device recognition in Great Britain (February 2026), and an international reliance framework with the US FDA launched in October 2025 alongside the UK National AI Commission. Adjacent bodies include the Commission on Human Medicines and the British Pharmacopoeia Commission, and its chemical laboratories have been consolidated into a new £20 million LGC Group National Laboratories facility in Guildford opened October 2025.

MHRA's business model is non-commercial: it is funded through HM Treasury grant-in-aid and supplementary public-sector grants (e.g., £10 million from HM Treasury in March 2023, £1 million in January 2023, and additional tranches from the Department of Health and Social Care, BEIS, and Wellcome Trust between 2022 and 2026) rather than through product pricing or fees disclosed in commercial terms. Its GTM motion is event- and policy-driven: public consultations, government funding announcements, regulatory sandbox cohort selections (e.g., AI Airlock), and bilateral partnerships (FDA, NICE). Primary customers/regulated populations include pharmaceutical and biotechnology companies (drug sponsors), medical device manufacturers, AI MedTech developers, and patient safety stakeholders. MHRA's distribution channels are government press releases, public consultations, and structured regulatory engagement programmes; it does not sell software or commercial products.

Name

Medicines and Healthcare products Regulatory Agency

Legal name

Medicines and Healthcare products Regulatory Agency

Website

https://gov.uk

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MHRA is the UK executive agency that regulates medicines, medical devices, and blood components, serving pharmaceutical companies, device manufacturers, and AI MedTech developers through statutory approval pathways, the AI Airlock regulatory sandbox, and bilateral partnerships with the US FDA and NICE.

Ownership category

akta.pro rank

Product category

Healthcare Regulatory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAJADAA

Drug Regulators (Human Pharmaceuticals)

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJAIAA

National Public Health Reference Laboratories

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

SECONDARYHLAJACAF

Health Technology Assessment (HTA) & Reimbursement Policy Bodies

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

SECONDARYBPADANAJ

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation

Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

• Healthcare regulatory services
• Pharmaceutical regulation
• Medical device approval
• AI medical device sandbox
• Medicines licensing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Others

Revenue model

1. UK government grant funding: Direct funding from HM Treasury (£10 million announced March 2023) and other government sources (£1 million for regulatory innovation projects) to accelerate access to innovative medical products and advance regulatory innovation.

Go-to-market motion1 record

Marketing channels3 records

Core offering

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK executive agency that regulates medicines, medical devices and blood components for transfusion. It grants marketing authorisations for new medicines and biologics, provides scientific advice and pre-submission meetings, runs post-market surveillance, and operates regulatory sandboxes (including the AI Airlock programme) to enable safe, timely access to innovative medical products in the UK.

Product overview

Medicines and Healthcare products Regulatory Agency (MHRA) operates as a UK government regulatory agency rather than a unified software product, offering a portfolio of regulatory programmes, frameworks, and pathways that together form its service offering. Its core programmes include the AI Airlock Programme (a regulatory sandbox for AI as a Medical Device, launched 2024 with Phase 2 in October 2025) and the MHRA-NICE Aligned Pathway for Medicine Regulation (launched March 2026) for streamlined medicine approvals. Supporting frameworks include the CE-Marked Medical Devices Recognition Framework (extending CE-mark recognition in Great Britain) and the MHRA-FDA International Reliance Framework (a partnership with the U.S. FDA announced October 2025 for global regulatory harmonisation). The agency's infrastructure services encompass the MHRA Chemical Laboratories (consolidated into the new £20 million LGC Group National Laboratories in Guildford in October 2025) and the AI MedTech Regulatory Oversight Programme (focusing on patient safety and post-market surveillance for AI medical technologies). Together, these offerings position MHRA as a regulator accelerating patient access to innovative medicines, medical devices, and AI-powered healthcare technologies.

Differentiator

Problem solved

Functional benefit

Brands

• AI Airlock: MHRA's regulatory sandbox programme for testing AI as a Medical Device (launched 2024).

Products and services

• AI Airlock Programme A regulatory sandbox programme for testing AI as a Medical Device (AIaMD), selecting emerging AI-powered medical technologies through phased cohorts to expand real-world testing, refine AI regulation models, and improve clinical decision-making and early disease detection. For AI MedTech developers and innovators seeking regulatory engagement for novel AI medical devices.
• MHRA-NICE Aligned Pathway for Medicine Regulation An aligned regulatory pathway jointly operated with NICE to streamline and expedite the regulation and approval of medicines in the UK through coordinated assessment. For pharmaceutical and biotechnology companies seeking UK marketing authorisation.
• CE-Marked Medical Devices Recognition Framework Regulatory framework proposing extension of recognition of CE-marked medical devices in Great Britain to support supply stability and innovation, including alignment with EU standards and an international reliance pathway for certain devices. For medical device manufacturers seeking UK market authorisation.
• MHRA-FDA International Reliance Framework Reliance framework partnership between UK MHRA and the U.S. FDA announced in October 2025 to accelerate access to medical technologies and AI in healthcare, including the launch of the UK National AI Commission and joint efforts to promote global regulatory harmonisation and faster approval of medical innovations.
• MHRA Chemical Laboratories MHRA's chemical laboratories consolidated into the £20 million LGC Group National Laboratories facility in Guildford, unifying the National Measurement Laboratory, the Office of the Government Chemist, and MHRA's chemical laboratories to support measurement science, public health, and regulatory standards.
• AI MedTech Regulatory Oversight Programme MHRA programme advised by experts and the Patient Safety Commissioner that prioritises patient safety in the regulation of AI MedTech, focusing on involving patients in decision-making and enhancing post-market surveillance to prevent harm and improve safety outcomes.

Quantifiable outcome

• £10 million in HM Treasury funding secured to accelerate access to innovative medical products (March 2023).
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature4 records

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines and Healthcare products Regulatory Agency